207 related articles for article (PubMed ID: 7614471)
21. Recombinant immunotoxins containing the VH or VL domain of monoclonal antibody B3 fused to Pseudomonas exotoxin.
Brinkmann U; Lee BK; Pastan I
J Immunol; 1993 Apr; 150(7):2774-82. PubMed ID: 8454854
[TBL] [Abstract][Full Text] [Related]
22. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME
Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895
[TBL] [Abstract][Full Text] [Related]
23. Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice.
Reiter Y; Wright AF; Tonge DW; Pastan I
Int J Cancer; 1996 Jul; 67(1):113-23. PubMed ID: 8690511
[TBL] [Abstract][Full Text] [Related]
24. Preparation and characterization of fusion protein truncated Pseudomonas Exotoxin A (PE38KDEL) in Escherichia coli.
Song S; Xue J; Fan K; Kou G; Zhou Q; Wang H; Guo Y
Protein Expr Purif; 2005 Nov; 44(1):52-7. PubMed ID: 15922623
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-4 receptors expressed on tumor cells may serve as a target for anticancer therapy using chimeric Pseudomonas exotoxin.
Debinski W; Puri RK; Pastan I
Int J Cancer; 1994 Sep; 58(5):744-8. PubMed ID: 8077061
[TBL] [Abstract][Full Text] [Related]
26. A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies.
Buchner J; Pastan I; Brinkmann U
Anal Biochem; 1992 Sep; 205(2):263-70. PubMed ID: 1332541
[TBL] [Abstract][Full Text] [Related]
27. Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses.
Kreitman RJ; Pastan I
Cancer Res; 1998 Mar; 58(5):968-75. PubMed ID: 9500458
[TBL] [Abstract][Full Text] [Related]
28. Recombinant immunotoxins: new therapeutic agents for cancer treatment.
Pastan IH
Cancer Detect Prev; 1993; 17(2):289-93. PubMed ID: 8402714
[TBL] [Abstract][Full Text] [Related]
29. Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma.
Puri RK
Toxicol Pathol; 1999; 27(1):53-7. PubMed ID: 10367674
[TBL] [Abstract][Full Text] [Related]
30. Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model.
Kreitman RJ; Chang CN; Hudson DV; Queen C; Bailon P; Pastan I
Int J Cancer; 1994 Jun; 57(6):856-64. PubMed ID: 8206679
[TBL] [Abstract][Full Text] [Related]
31. An immunotoxin with increased activity and homogeneity produced by reducing the number of lysine residues in recombinant Pseudomonas exotoxin.
Debinski W; Pastan I
Bioconjug Chem; 1994; 5(1):40-6. PubMed ID: 8199233
[TBL] [Abstract][Full Text] [Related]
32. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor.
Kreitman RJ; Pastan I
Biochem J; 1995 Apr; 307 ( Pt 1)(Pt 1):29-37. PubMed ID: 7717988
[TBL] [Abstract][Full Text] [Related]
33. Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent.
Debinski W; Pastan I
Cancer Res; 1992 Oct; 52(19):5379-85. PubMed ID: 1394141
[TBL] [Abstract][Full Text] [Related]
34. Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation.
Kuan CT; Pastan I
Proc Natl Acad Sci U S A; 1996 Feb; 93(3):974-8. PubMed ID: 8577771
[TBL] [Abstract][Full Text] [Related]
35. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions.
Reiter Y; Brinkmann U; Kreitman RJ; Jung SH; Lee B; Pastan I
Biochemistry; 1994 May; 33(18):5451-9. PubMed ID: 7910034
[TBL] [Abstract][Full Text] [Related]
36. Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer.
Pai LH; Bookman MA; Ozols RF; Young RC; Smith JW; Longo DL; Gould B; Frankel A; McClay EF; Howell S
J Clin Oncol; 1991 Dec; 9(12):2095-103. PubMed ID: 1960550
[TBL] [Abstract][Full Text] [Related]
37. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin.
Batra JK; Kasprzyk PG; Bird RE; Pastan I; King CR
Proc Natl Acad Sci U S A; 1992 Jul; 89(13):5867-71. PubMed ID: 1352878
[TBL] [Abstract][Full Text] [Related]
38. Independent domain folding of Pseudomonas exotoxin and single-chain immunotoxins: influence of interdomain connections.
Brinkmann U; Buchner J; Pastan I
Proc Natl Acad Sci U S A; 1992 Apr; 89(7):3075-9. PubMed ID: 1557415
[TBL] [Abstract][Full Text] [Related]
39. Recombinant immunotoxin containing a disulfide-stabilized Fv directed at erbB2 that does not require proteolytic activation.
Kuan CT; Pastan I
Biochemistry; 1996 Mar; 35(9):2872-7. PubMed ID: 8608123
[TBL] [Abstract][Full Text] [Related]
40. IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein.
Joshi BH; Leland P; Silber J; Kreitman RJ; Pastan I; Berger M; Puri RK
Br J Cancer; 2002 Jan; 86(2):285-91. PubMed ID: 11870521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
